Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
about
Bisphosphonates and other bone agents for breast cancerBisphosphonates for breast cancerBisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysisBisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell lineBisphosphonates for the relief of pain secondary to bone metastases.Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.Trends in Cancer Pain Management.Biochemical markers and skeletal metastases.Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.Prostate cancer: 10. Palliative care.Malignant bone pain: pathophysiology and treatments.Use of bisphosphonates in skeletal metastasis.Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care.Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trialsEvidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.Treatment of bone tumours by radiofrequency thermal ablation.Going beyond efficacy: strategies for cancer pain management.Bone mineral density in multiple myeloma patients after intravenous clodronate therapy.The role of disodium pamidronate in the management of bone pain due to malignancy.Bisphosphonates and other bone agents for breast cancer.
P2860
Q24203656-A6DDA3CC-4302-4A6E-B06D-15D90EEF4765Q24246519-F1C22A64-B666-4EA5-9111-E32DC4849A4FQ24608900-37DB94A2-6DC8-45F4-98F5-AB1F154A7DE6Q28361973-7526291A-029C-42E6-BAA0-2AB2901AC6BCQ32139406-36A66374-01F1-4A3B-9CCE-3C3C4B4F1418Q33809965-B516FE65-8394-4DD0-882C-E3EE3FCEC53DQ33887619-DFC45FA2-C323-464B-B39F-A69E1A394DA3Q33970475-7FD70DB4-8C6B-42C3-958F-596645E3E663Q33970512-1F776ECE-59A1-41D9-976E-2359FE835CD6Q34030661-9B2B836F-10E6-48DD-AACA-4661970C243EQ34040552-15A542CF-8C83-428F-927D-7EEB2DEC4DC1Q34065811-70DDE6FB-7011-463E-812E-094D0A3086CAQ34162842-CA5E049A-85CB-48BC-8547-F5AA5FD793F4Q35650666-4C2B2D75-396D-4297-A275-C0775416B6A5Q38785899-D778D841-8A65-4C4A-81F4-11AB8FF00F8DQ39303152-82745099-30F5-4B79-B18E-09883F61FA57Q42976344-743E20BE-534F-4716-914F-C3F9556F4292Q43623616-09B80B3D-8267-4FDC-ADBC-6A873BB330E2Q44020440-EB878194-B8C2-4826-92C2-687D1C7F8CD5Q47693752-04DD9E61-0848-40AF-8CFA-E78976A5684F
P2860
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Should bisphosphonates be part ...... ers? An evidence-based review.
@en
type
label
Should bisphosphonates be part ...... ers? An evidence-based review.
@en
prefLabel
Should bisphosphonates be part ...... ers? An evidence-based review.
@en
P1476
Should bisphosphonates be part ...... ers? An evidence-based review.
@en
P2093
D J Bloomfield
P304
P356
10.1200/JCO.1998.16.3.1218
P407
P577
1998-03-01T00:00:00Z